CRISPR/Cas9 genome engineering in hematopoietic cells
- The development of genome editing tools capable of modifying specific genomic sequences with unprecedented accuracy has opened up a wide range of new possibilities in targeted gene manipulation. In particular, the CRISPR/Cas9 system, a repurposed prokaryotic adaptive immune system, has been widely adopted because of its unmatched simplicity and flexibility. In this review we discuss achievements and current limitations of CRISPR/Cas9 genome editing in hematopoietic cells with special emphasis on its potential use in ex vivo gene therapy of monogenic blood disorders, HIV and cancer.
Author: | Duran SürünORCiDGND, Harald von Melchner, Frank SchnütgenORCiDGND |
---|---|
URN: | urn:nbn:de:hebis:30:3-514012 |
DOI: | https://doi.org/10.1016/j.ddtec.2018.08.001 |
ISSN: | 1740-6749 |
Pubmed Id: | https://pubmed.ncbi.nlm.nih.gov/30205879 |
Parent Title (English): | Drug discovery today. Technologies |
Publisher: | Elsevier |
Place of publication: | Amsterdam [u.a.] |
Contributor(s): | Milena Bellin |
Document Type: | Article |
Language: | English |
Year of Completion: | 2018 |
Date of first Publication: | 2018/08/25 |
Publishing Institution: | Universitätsbibliothek Johann Christian Senckenberg |
Release Date: | 2019/10/21 |
Volume: | 28 |
Page Number: | 7 |
First Page: | 33 |
Last Page: | 39 |
Note: | © 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
HeBIS-PPN: | 455688702 |
Institutes: | Medizin / Medizin |
Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Sammlungen: | Universitätspublikationen |
Licence (German): | ![]() |